Benchmark Rates Prenetics Global (PRE) buy, $30 Price Target
Benchmark maintains its positive view on Prenetics Global Limited with a $30 price target as the stock changes hands around $20.48, a 46.48% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Benchmark rated Prenetics Global Limited ($PRE) "buy" with a $30 price target on June 16, 2026.
Since the rating, $PRE is down 2.9% after 1 week, down 7.8% after 1 month and down 9.7% to date (from the $20.51 close on Jun 16, 2026).
PRE
Prenetics Global Limited
Key Points
- Benchmark analyst Bill Sutherland reaffirmed a buy rating on Prenetics Global Limited on June 16, 2026, pointing to a price target of $30.00.
- Benchmark's $30 price target implies 46.48% upside from Prenetics Global Limited's ($PRE) current $20.48 share price.
- The stock traded at $20.48 on Wednesday, leaving a wide gap between its current price and targets set by Wall Street firms.
- Wall Street maintains a strong buy consensus on the company backed by seven analyst opinions and an average target price of $35.86.
Get $PRE trade alerts by text
We text you when insiders, Congress or big funds trade $PRE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Prenetics Global Limited alert may contain errors. Disclosures
Benchmark Keeps Buy Rating on Prenetics Global Stock
Benchmark analyst Bill Sutherland kept a buy rating on Prenetics Global Limited ticker PRE on June 16, 2026, setting a price target of $30.00. The update keeps the firm in the bullish camp for the consumer health sciences company as researchers map out future expectations for the brand.
$PRE price target
Prenetics Global Limited daily closes and this analyst's $30 target. Not advice.
Stock Trades Well Below Analyst Targets
Shares of Prenetics Global changed hands at $20.48 on Wednesday. That price sits below the $30.00 target issued by Benchmark and even further away from the broader Wall Street consensus. The stock has moved between a 52-week low of $11.37 and a 52-week high of $27.24 over the past year. Its 50-day moving average rests at $21.34, while the 200-day moving average stands at $18.92.
Wall Street Coverage and Analyst Sentiment
Other financial firms have also weighed in on Prenetics Global in recent months. On October 12, 2026, Lucid Capital Markets initiated coverage with a buy rating and a $54.00 target. Earlier, Craig-Hallum started coverage with a buy rating and a $40.00 target on September 17, 2026. B. Riley Securities also launched coverage with a buy rating and a $37.00 target on August 27, 2026, while Benchmark maintained a buy rating with a $40.00 target on July 15, 2026. Across seven analyst opinions, the stock holds a strong buy consensus with a mean target price of $35.86, with targets ranging from a low of $30.00 to a high of $40.00.
What Prenetics Global Does
Based in Quarry Bay, Hong Kong, Prenetics Global Limited operates as a consumer health sciences business focused on human health and longevity products under the IM8 brand, alongside its CircleDNA genetic testing line. The company connects consumers with sequencing technology to deliver personalized wellness reports. It navigates the consumer defensive sector with a market capitalization of roughly $408.4 million.
Earnings and Upcoming Financial Reports
Investors will look toward the company's next earnings report scheduled for November 10, 2026, for further updates on financial performance and longevity product rollouts. The firm's trailing results reflect a net margin of negative 30.4% and an annual revenue of $154.59 million, alongside a negative price-to-earnings ratio due to ongoing losses.
Related Filing Alerts
Source: Benchmark's rating change on $PRE (Jun 16, 2026). Written by software, not financial advice. How we make alerts